Related Experiment Video

Updated: May 13, 2026

Quantifying Cognitive Decrements Caused by Cranial Radiotherapy
10:10

Quantifying Cognitive Decrements Caused by Cranial Radiotherapy

Published on: October 18, 2011

12.6K

A pilot study on the neurocognitive effect of sorafenib on patients with desmoid tumours: the SORA-COG study

Kamboji Sharanya1, Lulu Abdul Khader1, Fathima Shahama Oliyath Vazhayil1

  • 1All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India.

Ecancermedicalscience
|June 10, 2025
PubMed
Abstract

Insights

Sorafenib treatment for desmoid tumors (DTs) may increase anxiety in patients compared to healthy individuals. Longer treatment duration correlated with higher anxiety levels, suggesting a need for further research into sorafenib

Area of Science:

  • Neuroscience
  • Oncology
  • Pharmacology

Background:

  • Sorafenib, a multikinase inhibitor, is used for desmoid tumors (DTs).
  • Prolonged sorafenib use may cause cognitive impairment by inhibiting angiogenesis.
  • Neurocognitive effects of sorafenib in DT patients are not well-documented.

Purpose of the Study:

  • To investigate the neurocognitive effects of sorafenib in patients with desmoid tumors.
  • To assess anxiety, stress, and cognitive function in DT patients on sorafenib compared to controls.

Main Methods:

  • Cross-sectional study with 50 participants: 30 DT patients on sorafenib, 10 treatment-naive DT patients, 10 healthy controls.
  • Utilized questionnaires (Appearance Anxiety Inventory, DASS-21) and neuropsychological tests (HMSE, CANTAB).
  • Statistical analysis included Kruskal-Wallis test; p<0.05 considered significant.

Main Results:

  • Patients on sorafenib (Group 1) showed significantly higher anxiety (p=0.0127) than healthy controls (Group 3).
  • No significant differences in other objective cognitive/neuropsychological parameters were observed between groups.
  • Positive correlation found between sorafenib duration and anxiety (p=0.026); negative correlation between HMSE and reaction time (p=0.04).

Conclusions:

  • This is the first study on sorafenib's neurocognitive effects in DT patients.
  • DT patients on sorafenib exhibit increased anxiety compared to healthy controls.
  • Further longitudinal studies are recommended to evaluate sorafenib's long-term impact on cognitive function in DT.
Keywords:
desmoidfibromatosisneurocognitionsorafenibtyrosine kinase inhibitors

More Related Videos

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.2K
Author Spotlight: Developing Multiplexed Kinetic Assays for Organoid-Based Drug Response Analysis09:13

Author Spotlight: Developing Multiplexed Kinetic Assays for Organoid-Based Drug Response Analysis

Published on: January 5, 2024

1.1K

Related Concept Videos

Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...